BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966-4972. [PMID: 19720913 DOI: 10.1200/jco.2008.21.6630] [Cited by in Crossref: 198] [Cited by in F6Publishing: 83] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Bakr NM, Mahmoud MS, Nabil R, Boushnak H, Swellam M. Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes. J Genet Eng Biotechnol 2021;19:84. [PMID: 34089425 DOI: 10.1186/s43141-021-00174-7] [Reference Citation Analysis]
2 Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32. [PMID: 20198462 DOI: 10.1208/s12248-010-9181-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 6.2] [Reference Citation Analysis]
3 Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, Gómez A, González Del Val R, López-Miranda E, Martín-Angulo M, Martínez-Jañez N, Olier C, Zamora P. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol 2015;22:e51-60. [PMID: 25908921 DOI: 10.3747/co.22.2210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
4 Kim D, Lee J, Kang J, Kim SH, Yoo TK, Oh S, Lee A. Notch1 in Tumor Microvascular Endothelial Cells and Tumoral miR-34a as Prognostic Markers in Locally Advanced Triple-Negative Breast Cancer. J Breast Cancer 2019;22:562-78. [PMID: 31897330 DOI: 10.4048/jbc.2019.22.e56] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pories SE, Wulf GM. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) 2010;2:37-44. [PMID: 24367165 DOI: 10.2147/bctt.s6511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
6 Fujii Y, Hirahara N, Kaji S, Taniura T, Hyakudomi R, Yamamoto T, Tajima Y. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature. J Med Case Rep 2018;12:84. [PMID: 29580267 DOI: 10.1186/s13256-018-1619-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med 2019;9:E84. [PMID: 31905724 DOI: 10.3390/jcm9010084] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 34.5] [Reference Citation Analysis]
8 Power DG, Kemeny NE. Nasal septum perforation and bevacizumab. Med Oncol 2011;28:89-93. [PMID: 20213219 DOI: 10.1007/s12032-010-9464-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Vitry A, Nguyen T, Entwistle V, Roughead E. Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study. J Pharm Policy Pract 2015;8:25. [PMID: 26483954 DOI: 10.1186/s40545-015-0046-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
10 Munagala R, Aqil F, Gupta RC. Promising molecular targeted therapies in breast cancer. Indian J Pharmacol 2011;43:236-45. [PMID: 21713084 DOI: 10.4103/0253-7613.81497] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
11 Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An audit strategy for progression-free survival. Biometrics 2011;67:1092-9. [PMID: 21210772 DOI: 10.1111/j.1541-0420.2010.01539.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
12 Liu X, Liu X, Qiao T, Chen W, Yuan S. Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials. Onco Targets Ther 2016;9:3771-81. [PMID: 27445484 DOI: 10.2147/OTT.S103954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
13 Lebok P, Huber J, Burandt EC, Lebeau A, Marx AH, Terracciano L, Heilenkötter U, Jänicke F, Müller V, Paluchowski P, Geist S, Wilke C, Simon R, Sauter G, Quaas A. Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. Mol Med Rep 2016;14:1443-50. [PMID: 27357606 DOI: 10.3892/mmr.2016.5430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Kümmel S, Jackisch C, Müller V, Schneeweiss A, Klawitter S, Lux MP. Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit? Cancer Manag Res 2018;10:5423-31. [PMID: 30519090 DOI: 10.2147/CMAR.S177240] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Hirai F, Seto T, Inamasu E, Shimokawa M, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y. Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncol Lett 2015;9:2577-82. [PMID: 26137109 DOI: 10.3892/ol.2015.3086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol 2012;30:3444-7. [PMID: 22927522 DOI: 10.1200/JCO.2012.41.9580] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
17 Wakamatsu T, Naka N, Sasagawa S, Tanaka T, Takenaka S, Araki N, Ueda T, Nishizawa Y, Yoshikawa H, Itoh K. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma. Cancer Sci 2014;105:1124-34. [PMID: 24975049 DOI: 10.1111/cas.12469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
18 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
19 Van der Veldt AA, Lammertsma AA, Smit EF. Scheduling of anticancer drugs: timing may be everything. Cell Cycle. 2012;11:4339-4343. [PMID: 23032365 DOI: 10.4161/cc.22187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
20 Tsai WC, Chang KM, Kao KJ. Dynamic Contrast Enhanced MRI and Intravoxel Incoherent Motion to Identify Molecular Subtypes of Breast Cancer with Different Vascular Normalization Gene Expression. Korean J Radiol 2021;22:1021-33. [PMID: 34047501 DOI: 10.3348/kjr.2020.0760] [Reference Citation Analysis]
21 Untch M, Würstlein R, Lüftner D, Haidinger R, Fasching PA, Augustin D, Briest S, Ettl J, Förster F, Kurbacher CM, Lück HJ, Marschner N, Müller L, Müller V, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K, Thomssen C, Harbeck N. ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results. Geburtshilfe Frauenheilkd 2020;80:588-600. [PMID: 32565549 DOI: 10.1055/a-1139-9380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther 2009;9:1715-25. [PMID: 19954282 DOI: 10.1586/era.09.153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
23 Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 2012;17:191-204. [PMID: 22836913 DOI: 10.1007/s10911-012-9263-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 8.8] [Reference Citation Analysis]
24 Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann PU, Jírů-Hillmann S, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Baumgartner T, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching P, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Stangl S. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018;78:1056-88. [PMID: 30581198 DOI: 10.1055/a-0646-4630] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
25 Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10. [PMID: 22500155 DOI: 10.4143/crt.2012.44.1.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
26 Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs 2014;32:1285-94. [PMID: 24894652 DOI: 10.1007/s10637-014-0122-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
27 Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer 2019;120:475-80. [PMID: 30745582 DOI: 10.1038/s41416-019-0391-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 18.5] [Reference Citation Analysis]
28 Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol 2012;70:49-56. [PMID: 22729159 DOI: 10.1007/s00280-012-1887-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
29 Kawajiri H, Takashima T, Onoda N, Kashiwagi S, Noda S, Ishikawa T, Wakasa K, Hirakawa K. Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer. Oncol Lett 2012;4:612-6. [PMID: 23205071 DOI: 10.3892/ol.2012.801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
30 Inoue K, Ninomiya J, Saito T, Kimizuka K, Kurosumi M. Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators. BMC Cancer 2018;18:671. [PMID: 29925345 DOI: 10.1186/s12885-018-4556-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
31 Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011;11:155-80. [PMID: 21453286 DOI: 10.2174/156652311795684722] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
32 Di Salvatore M, Lo Giudice L, Rossi E, Santonocito C, Nazzicone G, Rodriquenz MG, Cappuccio S, Inno A, Fuso P, Orlandi A, Strippoli A, Capoluongo E, Astone A, Cassano A, Barone C. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. Clin Transl Oncol 2016;18:40-6. [PMID: 26141413 DOI: 10.1007/s12094-015-1334-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
33 Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, Su S, Wang Q, Jin L, Wang Y, Lau WY, Jiang Z, Song E. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer 2020;8:e000696. [PMID: 32448804 DOI: 10.1136/jitc-2020-000696] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
34 Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12:699-709. [PMID: 23001349 DOI: 10.1038/nrc3366] [Cited by in Crossref: 172] [Cited by in F6Publishing: 161] [Article Influence: 19.1] [Reference Citation Analysis]
35 Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
36 Lohmann AE, Chia S. Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it? Curr Treat Options Oncol 2012;13:249-62. [PMID: 22350496 DOI: 10.1007/s11864-012-0181-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
37 Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. In Vivo 2020;34:1377-86. [PMID: 32354934 DOI: 10.21873/invivo.11917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Li MY, Lv YC, Tong LJ, Peng T, Qu R, Zhang T, Sun YM, Chen Y, Wei LX, Geng MY, Duan WH, Xie H, Ding J. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Acta Pharmacol Sin 2016;37:398-407. [PMID: 26806300 DOI: 10.1038/aps.2015.117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
39 Montero AJ, Escobar M, Lopes G, Glück S, Vogel C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 2012;14:1-11. [PMID: 22012632 DOI: 10.1007/s11912-011-0202-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
40 Müller V, Witzel I, Stickeler E. Immunological Approaches in the Treatment of Metastasized Breast Cancer. Breast Care (Basel) 2009;4:359-66. [PMID: 20877670 DOI: 10.1159/000262454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
41 Zhu X, Tian X, Yu C, Hong J, Fang J, Chen H. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore) 2016;95:e4232. [PMID: 27559943 DOI: 10.1097/MD.0000000000004232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
42 Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 2012;18:2374-81. [PMID: 22344231 DOI: 10.1158/1078-0432.CCR-11-2275] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
43 Yonucu S, Yιlmaz D, Phipps C, Unlu MB, Kohandel M. Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. PLoS Comput Biol 2017;13:e1005724. [PMID: 28922358 DOI: 10.1371/journal.pcbi.1005724] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
44 Petrelli F, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. Med Oncol 2014;31:776. [PMID: 24271313 DOI: 10.1007/s12032-013-0776-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
45 Bischoff J, Ignatov A. The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer. Breast Care (Basel) 2010;5:134-41. [PMID: 20847826 DOI: 10.1159/000314996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T, Notsu A. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. Sci Rep 2021;11:6328. [PMID: 33737682 DOI: 10.1038/s41598-021-85948-2] [Reference Citation Analysis]
47 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 83] [Article Influence: 17.7] [Reference Citation Analysis]
48 Kaiser LD, Melemed AS, Preston AJ, Chaudri Ross HA, Niedzwiecki D, Fyfe GA, Gough JM, Bushnell WD, Stephens CL, Mace MK, Abrams JS, Schilsky RL. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol 2010;28:5046-53. [PMID: 20921453 DOI: 10.1200/JCO.2010.29.6608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
49 Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011;71:2213-29. [PMID: 22035518 DOI: 10.2165/11207720-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
50 Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R. An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clin Trials 2013;10:754-60. [PMID: 23935162 DOI: 10.1177/1740774513493973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Braun D, Gorfine M, Katki HA, Ziogas A, Parmigiani G. Nonparametric Adjustment for Measurement Error in Time-to-Event Data: Application to Risk Prediction Models. J Am Stat Assoc 2018;113:14-25. [PMID: 30093737 DOI: 10.1080/01621459.2017.1311261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Goldfarb SB, Hudis C, Dickler MN. Bevacizumab in metastatic breast cancer: when may it be used? Ther Adv Med Oncol 2011;3:85-93. [PMID: 21789158 DOI: 10.1177/1758834010397627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
53 Bohndiek SE, Kettunen MI, Hu DE, Brindle KM. Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res 2012;72:854-64. [PMID: 22223844 DOI: 10.1158/0008-5472.CAN-11-2795] [Cited by in Crossref: 55] [Cited by in F6Publishing: 30] [Article Influence: 6.1] [Reference Citation Analysis]
54 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. J Gastrointest Oncol 2014;5:99-103. [PMID: 24772337 DOI: 10.3978/j.issn.2078-6891.2014.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
56 Kruse V, Denys H, Van Den Broecke R, Van Belle S, Cocquyt V. The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most? Springerplus 2013;2:202. [PMID: 23710429 DOI: 10.1186/2193-1801-2-202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Yamakawa M, Doh SJ, Santosa SM, Montana M, Qin EC, Kong H, Han KY, Yu C, Rosenblatt MI, Kazlauskas A, Chang JH, Azar DT. Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. Med Res Rev 2018;38:1769-98. [PMID: 29528507 DOI: 10.1002/med.21496] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
58 Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res Treat 2016;160:305-12. [PMID: 27714541 DOI: 10.1007/s10549-016-4001-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
59 Zhen Z, Sun X, He Y, Cai Y, Wang J, Guan Z. The sequence of drug administration influences the antitumor effects of bevacizumab and cyclophosphamide in a neuroblastoma model. Med Oncol 2011;28 Suppl 1:S619-25. [PMID: 20844988 DOI: 10.1007/s12032-010-9664-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
60 Tian Y, Zhai X, Tian H, Jing W, Zhu H, Yu J. Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. Cancer Manag Res 2019;11:10083-92. [PMID: 31819641 DOI: 10.2147/CMAR.S222910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Wang X, Huang C, Li M, Gu Y, Cui Y, Li Y. The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials. Tumour Biol 2014;35:4841-8. [PMID: 24570182 DOI: 10.1007/s13277-014-1635-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
62 Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol 2012;2012:281261. [PMID: 21876693 DOI: 10.1155/2012/281261] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
63 Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat 2013;139:411-9. [PMID: 23649189 DOI: 10.1007/s10549-013-2552-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
64 Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf 2012;35:15-25. [PMID: 22136182 DOI: 10.2165/11595910-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
65 Yano H, Nakayama N, Morimitsu K, Futamura M, Ohe N, Miwa K, Shinoda J, Iwama T. Changes in protein level in the cerebrospinal fluid of a patient with cerebral radiation necrosis treated with bevacizumab. Clin Med Insights Oncol 2014;8:153-7. [PMID: 25574147 DOI: 10.4137/CMO.S19823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
66 El Sayed R, El Jamal L, El Iskandarani S, Kort J, Abdel Salam M, Assi H. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Front Oncol 2019;9:510. [PMID: 31281796 DOI: 10.3389/fonc.2019.00510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
67 Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer 2017;116:1425-35. [PMID: 28441382 DOI: 10.1038/bjc.2017.116] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
68 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
69 Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer 2016;7:1901-6. [PMID: 27698931 DOI: 10.7150/jca.15802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
70 Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer 2021;28:145-60. [PMID: 32715420 DOI: 10.1007/s12282-020-01138-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Spano JP, Falandry C, Chaibi P, Freyer G. Current targeted therapies in breast cancer: clinical applications in the elderly woman. Oncologist 2011;16:1144-53. [PMID: 21705664 DOI: 10.1634/theoncologist.2011-0028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
72 Welt A, Marschner N, Lerchenmueller C, Decker T, Steffens CC, Koehler A, Depenbusch R, Busies S, Hegewisch-Becker S. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. Breast Cancer Res Treat 2016;156:97-107. [PMID: 26927446 DOI: 10.1007/s10549-016-3727-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
73 Thomssen C, Lüftner D, Untch M, Haidinger R, Würstlein R, Harbeck N, Augustin D, Briest S, Ettl J, Fasching PA, Förster F, Kurbacher CM, Lück HJ, Marschner N, Müller L, Müller V, Perlova-Griff L, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K. International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. Breast Care (Basel) 2020;15:82-95. [PMID: 32231503 DOI: 10.1159/000505957] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
74 Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y. A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. Cancer Med 2019;8:383-99. [PMID: 30525293 DOI: 10.1002/cam4.1892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
75 Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108:1052-1060. [PMID: 23422754 DOI: 10.1038/bjc.2013.69] [Cited by in Crossref: 115] [Cited by in F6Publishing: 95] [Article Influence: 14.4] [Reference Citation Analysis]
76 Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, Miles D. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:561-574. [PMID: 20808300 DOI: 10.1038/nrclinonc.2010.122] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
77 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
78 Redondo A, Ramos Vázquez M, Manso L, Gil Gil MJ, Garau Llinas I, García-Garre E, Rodríguez CA, Chacón JI, López-Vivanco G. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study. Onco Targets Ther 2018;11:5845-52. [PMID: 30271167 DOI: 10.2147/OTT.S170303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011;30:54. [PMID: 21569417 DOI: 10.1186/1756-9966-30-54] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
80 Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Bevacizumab treatment for advanced breast cancer. Oncologist 2011;16:1684-97. [PMID: 21976315 DOI: 10.1634/theoncologist.2011-0113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
81 Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534-1540. [PMID: 22454414 DOI: 10.1200/JCO.2011.39.4767] [Cited by in Crossref: 313] [Cited by in F6Publishing: 180] [Article Influence: 34.8] [Reference Citation Analysis]
82 Liedtke C, Kiesel L. Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer. Breast Care (Basel) 2011;6:234-9. [PMID: 21779231 DOI: 10.1159/000328964] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
83 Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30:1705-1711. [PMID: 22430273 DOI: 10.1200/jco.2011.39.2613] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]